{'fraction_non_alphanumeric': 0.019175455417066157, 'fraction_numerical': 0.0, 'mean_word_length': 5.444444444444445, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Identification of hemangioblasts provides hope for blood cell engineering

Researchers from Johns Hopkins University (MD, USA) believe they have found a way to identify the earliest form of human blood stem cells. This research provides hope that in the future it will be possible to engineer blood cells in sufficient quantities to treat blood-related disorders, such as anemias, leukemia and autoimmune diseases. The researchers, led by Elias Zambidis, of the Institute of Cell Engineering at the Johns Hopkins University School of Medicine and the Division of Pediatric Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, found that angiotensin-converting enzyme (ACE) is a marker for identifying hemangioblasts from differentiating human embryonic stem cells. They also found that ACE and the renin– angiotensin system (RAS) regulate the expansion and differentiation of hemangioblasts. They suggest that the RAS could be exploited to direct human embryonic stem cells to either a hematopoietic or endothelial fate.